{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T09:17:10Z","timestamp":1648891030639},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0107273","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T23:00:34Z","timestamp":1413846034000},"page":"e107273","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis"],"prefix":"10.1371","volume":"9","author":[{"given":"Rinat","family":"Yerushalmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Goldvaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Sulkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Ben-Aharon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Neiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa Beatrice","family":"Ciuraru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor","family":"Amit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alona","family":"Zer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Granot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulamith","family":"Rizel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomon M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735","volume":"27","author":"S Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3747\/co.v17i2.498","article-title":"Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis","volume":"17","author":"T Vandenberg","year":"2010","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jjco\/hyp050","article-title":"Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients","volume":"39","author":"D Takabatake","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"ref5","article-title":"Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis","author":"N Ngamphaiboon","year":"2011","journal-title":"Med Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-010-0843-8","article-title":"Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy","volume":"19","author":"A Chan","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/COC.0b013e3181f94716","article-title":"Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective non-randomized study","volume":"34","author":"D Hendler","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1200\/JCO.2005.03.099","article-title":"Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide","volume":"23","author":"P Papaldo","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007913.pub2","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients","author":"P Renner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"TJ Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref11","article-title":"NCCN clinical practice guidelines in oncology","journal-title":"Myeloid Growth Factors"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"MS Aapro","year":"2011","journal-title":"Eur JCancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.critrevonc.2011.04.001","article-title":"Adjuvant docetaxel\/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study","volume":"80","author":"G Freyer","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"GH Lyman","year":"2013","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood.V88.8.2819.bloodjournal8882819","article-title":"Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals","volume":"88","author":"P Anderlini","year":"1996","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"ML Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","article-title":"Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma","volume":"21","author":"JM Vose","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"MD Green","year":"2003","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"FA Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.2011.37.7499","article-title":"Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer","volume":"30","author":"DL Hershman","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.2012.48.3644","article-title":"Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia","volume":"31","author":"MJ Aarts","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.3747\/co.v18i6.810","article-title":"The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer","volume":"18","author":"T Younis","year":"2011","journal-title":"Curr Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0107273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:04:45Z","timestamp":1598400285000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0107273"}},"subtitle":[],"editor":[{"given":"Lucia","family":"Gabriele","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,15]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0107273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,15]]}}}